State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis

被引：83

作者：

Singh, Vasvi ^{[1
,2
]}

Falk, Rodney ^{[3
]}

Di Carli, Marcelo F. ^{[1
,2
]}

Kijewski, Marie ^{[1
,2
]}

Rapezzi, Claudio ^{[4
]}

Dorbala, Sharmila ^{[1
,2
,3
,5
,6
]}

机构：

[1] Brigham & Womens Hosp, Div Nucl Med, 75 Francis St, Boston, MA 02115 USA

[2] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA

[3] Brigham & Womens Hosp, Cardiac Amyloidosis Program, 75 Francis St, Boston, MA 02115 USA

[4] Univ Bologna, Alma Mater Studiorum, Dept Expt Diagnost & Specialty Med, Cardiol, Bologna, Italy

[5] Brigham & Womens Hosp, Dept Med, Cardiac Amyloidosis Program, Cardiovasc Div,Heart & Vasc Ctr,Div Nucl Med, 75 Francis St, Boston, MA 02115 USA

[6] Harvard Med Sch, 75 Francis St, Boston, MA 02115 USA

来源：

JOURNAL OF NUCLEAR CARDIOLOGY | 2019年 / 26卷 / 01期

关键词：

Amyloid heart disease; SPECT; PET; modalities; molecular imaging; MYOCARDIAL INFARCTS; ETIOLOGIC DIAGNOSIS; AORTIC-STENOSIS; HEART-FAILURE; SCINTIGRAPHY; PYROPHOSPHATE; IDENTIFICATION; LOCALIZATION; PROGNOSIS; UTILITY;

D O I：

10.1007/s12350-018-01552-4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Cardiac amyloidosis, once considered untreatable, is now gaining well-deserved attention due to advances in imaging and the recent approval of targeted breakthrough therapies. In this paper, we discuss the role of radionuclide imaging in the evaluation and management of patients with the most common form of amyloidosiscardiac transthyretin amyloidosis (ATTR). We provide a comprehensive summary of the literature interspersed with our institutional experience as appropriate, to deliver our perspective.

引用

页码：158 / 173

页数：16

共 50 条

[21] Bone Scintigraphy Imaging for Transthyretin Cardiac Amyloidosis
Alexander, Kevin M.
Witteles, Ronald M.
JACC-CARDIOVASCULAR IMAGING, 2020, 13 (06) : 1322 - 1324
[22] Multimodality Imaging for Diagnosing Transthyretin Cardiac Amyloidosis
Manzil, Fathima Fijula Palot
Pandey, Tarun
CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (04)
[23] Hydroxymethylene diphosphonate for imaging transthyretin cardiac amyloidosis
Joseph C. Lee
Ramin Alipour
Journal of Nuclear Cardiology, 2020, 27 : 1040 - 1040
[24] Hydroxymethylene diphosphonate for imaging transthyretin cardiac amyloidosis
Lee, Joseph C.
Alipour, Ramin
JOURNAL OF NUCLEAR CARDIOLOGY, 2020, 27 (03) : 1040 - 1040
[25] The Role of Imaging in Diagnosing Transthyretin Cardiac Amyloidosis
Chaaban, Nourhan
Kshatriya, Shilpa
CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (06)
[26] Electrophysiological Manifestations of Cardiac Amyloidosis JACC: CardioOncology State-of-the-Art Review
Hartnett, Jack
Jaber, Wael
Maurer, Matthew
Sperry, Brett
Hanna, Mazen
Collier, Patrick
Patel, Divyang R.
Wazni, Oussama M.
Donnellan, Eoin
JACC: CARDIOONCOLOGY, 2021, 3 (04): : 506 - 515
[27] What is characteristic of transthyretin cardiac amyloidosis on imaging techniques?
Arana, X.
Goena, C.
Villanueva, I.
Rengel, A.
Manas, L.
Rilo, I.
Solla, I.
Querejeta, R.
EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 : 109 - 109
[28] State of the Art of Cardiac Amyloidosis
Belfeki, Nabil
Ghriss, Nouha
Monchi, Mehran
Moini, Cyrus
BIOMEDICINES, 2023, 11 (04)
[29] Diagnosis of cardiac transthyretin amyloidosis based on multimodality imaging
Kristina Dahlem
Guido Michels
Carsten Kobe
Alexander C. Bunck
Henrik ten Freyhaus
Roman Pfister
Clinical Research in Cardiology, 2017, 106 : 471 - 473
[30] Diagnosis of cardiac transthyretin amyloidosis based on multimodality imaging
Dahlem, Kristina
Michels, Guido
Kobe, Carsten
Bunck, Alexander C.
ten Freyhaus, Henrik
Pfister, Roman
CLINICAL RESEARCH IN CARDIOLOGY, 2017, 106 (06) : 471 - 473

← 1 2 3 4 5 →